Skip to content
Kiwi Biosciences logo

Kiwi Biosciences

Kiwi Biosciences is a YC Summer 2021 (S21) company. Based in Boston, MA, USA. Team of 10.

  • Biotech
  • Food Tech

About Kiwi Biosciences

GPAgent's own fund-neutral profile, written from public information. Updated Oct 4, 2026.

Summary

Kiwi Biosciences develops novel enzymes that break down FODMAP compounds in food before they can trigger digestive symptoms, targeting people with IBS and other FODMAP sensitivities. Its product, FODZYME, is added directly to meals, replacing the need to follow a strict low-FODMAP elimination diet. The company sells direct-to-consumer and also markets to clinicians.

Business model

Per-unit product purchases, HSA/FSA eligible, sold direct-to-consumer

Go-to-market

IBS sufferers and FODMAP-sensitive individuals buy FODZYME directly online; a parallel clinician-facing channel targets dietitians and gastroenterologists who recommend it to patients.

From the Y Combinator listing

How Kiwi Biosciences describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Patent-pending enzymes to break down common dietary triggers

Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food.

Facts

Industry
Healthcare / Healthcare -> Consumer Health and Wellness
Location
Boston, MA, USA
Team size
10
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works